Clinical Trial ResultsAlterity Therapeutics reported positive clinical results for its Phase 2 trial of ATH434 in Multiple System Atrophy, including 48% slowing of clinical progression at the 50 mg dose level.

Financial PositionThe balance sheet of Alterity Therapeutics has been strengthened, providing up to A$40M in additional funding which could extend the cash runway through CY26.

Market PotentialBased on the Phase 2 results, Alterity intends to engage the FDA to discuss next steps in the development of ATH434 in MSA, a disease with a small patient population but few treatment options.

Bears Say

Market SentimentThe recommendation on ATHE shares is being lowered, indicating potential concerns about future stock performance.

Stock RecommendationThe recommendation on ATHE shares is being lowered to Hold as these shares have exceeded the $4 price target.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

<0.01% Mutual Funds

0.11% Other Institutional Investors

99.88% Public Companies and

Individual Investors

Detailed Ownership Overview >

ATHE FAQ

What was Alterity Therapeutics Ltd’s price range in the past 12 months?

Alterity Therapeutics Ltd lowest stock price was $1.00 and its highest was $5.87 in the past 12 months.

What is Alterity Therapeutics Ltd’s market cap?

Alterity Therapeutics Ltd’s market cap is $90.02M.

When is Alterity Therapeutics Ltd’s upcoming earnings report date?

Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 218 days.

How were Alterity Therapeutics Ltd’s earnings last quarter?

Alterity Therapeutics Ltd released its earnings results on Feb 28, 2025. The company reported -$0.435 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.299.

Is Alterity Therapeutics Ltd overvalued?

According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alterity Therapeutics Ltd pay dividends?

Alterity Therapeutics Ltd does not currently pay dividends.

What is Alterity Therapeutics Ltd’s EPS estimate?

Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alterity Therapeutics Ltd have?

Alterity Therapeutics Ltd has 15,345,617 shares outstanding.

What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?

Alterity Therapeutics Ltd reported an EPS of -$0.435 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -2.326%.

Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?

Currently, no hedge funds are holding shares in ATHE

Alterity Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-154.88%

Trailing 12-Months

Asset Growth

-56.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alterity Therapeutics Ltd

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.